

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1-9. (canceled)

10. (currently amended) A complex of a ligand and a polypeptide, wherein the polypeptide comprises an amino acid sequence selected from (i) amino acids 40-60 of SEQ ID NO:7 (mouse synaptotagmin II botulinum toxin serotype B (BoNT/B)-binding domain), (ii) amino acids 40-60 of SEQ ID NO:9 (rat synaptotagmin II botulinum toxin serotype B (BoNT/B)-binding domain), and (iii) a fragment of a mouse or rat synaptotagmin II homolog that corresponds to (i) or (ii), that is homologous or at least 70% identical to a murine synaptotagmin II botulinum toxin serotype B (BoNT/B) binding domain at amino acid position 40 to 60, wherein the ligand is selected from ~~the group consisting of~~ BoNT/B and an antibody against said amino acid sequence, and wherein the ligand binds to the polypeptide at said amino acid sequence, with the proviso that where the polypeptide is a full length synaptotagmin, the ligand is not a botulinum toxin.

11-13. (canceled)

14. (currently amended) The complex of claim ~~50~~ 10, wherein the polypeptide comprises an amino acid sequence selected from ~~the group consisting of~~ amino acids 40-60 of SEQ ID NO:7 and amino acids 40-60 of SEQ ID NO:9.

15-41. (canceled)

42. (previously presented) The complex of claim 10, wherein the ligand is BoNT/B, and wherein the polypeptide is a synthetic or recombinant peptide.

43. (previously presented) The complex of claim 42, wherein the polypeptide has a sequence identical or homologous to a luminal domain of a synaptotagmin.